This company listing is no longer active
Laboratorio Reig Jofre Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 1/6
Laboratorio Reig Jofre's earnings have been declining at an average annual rate of -7.8%, while the Pharmaceuticals industry saw earnings growing at 13.8% annually. Revenues have been growing at an average rate of 9.1% per year. Laboratorio Reig Jofre's return on equity is 2.7%, and it has net margins of 2.1%.
Anahtar bilgiler
-7.8%
Kazanç büyüme oranı
-14.2%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 5.0% |
| Gelir büyüme oranı | 9.1% |
| Özkaynak getirisi | 2.7% |
| Net Marj | 2.1% |
| Sonraki Kazanç Güncellemesi | 26 Jul 2022 |
Yakın geçmiş performans güncellemeleri
Güncelleme yok
Recent updates
Güncelleme yok
Gelir ve Gider Dağılımı
Laboratorio Reig Jofre nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Dec 21 | 240 | 5 | 74 | 0 |
| 30 Sep 21 | 237 | 6 | 77 | 0 |
| 30 Jun 21 | 234 | 6 | 76 | 0 |
| 31 Mar 21 | 234 | 6 | 76 | 0 |
| 31 Dec 20 | 234 | 6 | 76 | 0 |
| 30 Sep 20 | 229 | 8 | 75 | 0 |
| 30 Jun 20 | 229 | 6 | 72 | 0 |
| 31 Mar 20 | 219 | 6 | 70 | 0 |
| 31 Dec 19 | 206 | 5 | 68 | 0 |
| 30 Sep 19 | 199 | 7 | 68 | 0 |
| 30 Jun 19 | 188 | 9 | 67 | 0 |
| 31 Mar 19 | 188 | 9 | 66 | 0 |
| 31 Dec 18 | 185 | 9 | 65 | 0 |
| 30 Sep 18 | 185 | 10 | 60 | 0 |
| 30 Jun 18 | 179 | 9 | 59 | 0 |
| 31 Mar 18 | 175 | 9 | 58 | 0 |
| 31 Dec 17 | 172 | 9 | 58 | 0 |
| 30 Sep 17 | 164 | 5 | 58 | 0 |
| 30 Jun 17 | 164 | 7 | 57 | 0 |
| 31 Mar 17 | 164 | 8 | 57 | 0 |
| 31 Dec 16 | 161 | 8 | 55 | 0 |
| 30 Sep 16 | 160 | 5 | 55 | 0 |
| 30 Jun 16 | 159 | 5 | 54 | 0 |
| 31 Mar 16 | 156 | 5 | 53 | 1 |
| 31 Dec 15 | 157 | 9 | 53 | 0 |
Kaliteli Kazançlar: RJF.D has high quality earnings.
Büyüyen Kar Marjı: RJF.D's current net profit margins (2.1%) are lower than last year (2.4%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: RJF.D's earnings have declined by 7.8% per year over the past 5 years.
Büyüme Hızlandırma: RJF.D's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Kazançlar vs. Sektör: RJF.D had negative earnings growth (-10.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (8.9%).
Özkaynak Getirisi
Yüksek ROE: RJF.D's Return on Equity (2.7%) is considered low.